Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK112 in Advanced Non-Small Cell Lung Cancer
NCT06225804Phase 1Active, not recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ABSK112 in non-small cell lung cancer (NSCLC), sponsored by Abbisko Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 50 months and 2 more. Started Feb 2024; status: active, not recruiting.
02
Drugs
ABSK112
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06225804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225804.